Motif Neurotech secures UK grant to pioneer therapeutic brain-computer interface technology
Motif Neurotech, a Houston-based innovator in neurotechnology, has received a multimillion-dollar award from the UK’s Advanced Research and Invention Agency (ARIA). The funding, under ARIA’s ... Read More
Johnson & Johnson seeks FDA approval for SPRAVATO in treatment-resistant depression
Johnson & Johnson (NYSE: JNJ) is seeking U.S. Food and Drug Administration (FDA) approval for SPRAVATO (esketamine) as a standalone treatment for adults with treatment-resistant ... Read More
Esketamine nasal spray misses key trial expectations, but Janssen remains optimistic
Janssen Pharmaceutical Companies of Johnson & Johnson encountered a significant setback with their esketamine nasal spray in a phase 3 trial aimed at treating patients ... Read More